Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
108M
-
Number of holders
-
131
-
Total shares
-
46.6M
-
Shares change
-
+11M
-
Total reported value, excl. options
-
$716M
-
Value change
-
+$139M
-
Put/Call ratio
-
0.66
-
Number of buys
-
90
-
Number of sells
-
-49
-
Price
-
$15.37
Significant Holders of Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI) as of Q1 2020
142 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - COMMON STOCK as of Q1 2020.
Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.6M shares
of 108M outstanding shares and own 43.19% of the company stock.
Largest 10 shareholders include FMR LLC (7.74M shares), VANGUARD GROUP INC (5.26M shares), BlackRock Inc. (4.44M shares), Bellevue Group AG (3.73M shares), WASATCH ADVISORS INC (2.93M shares), Consonance Capital Management LP (1.65M shares), DIMENSIONAL FUND ADVISORS LP (1.63M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.49M shares), STATE STREET CORP (1.23M shares), and SAMLYN CAPITAL, LLC (1.15M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.